BMS's Abecma Faces J&J Threat Despite Pivotal Success In Earlier Myeloma Setting
Both Rivals Tout Blockbuster Potential
Executive Summary
The US major’s CAR-T therapy is likely to win a label expansion to the large third-line-plus myeloma setting following positive Phase III data but a rival candidate from J&J could nab more of the market.
You may also be interested in...
Finance Watch: Summit Raises $500m For Shift From Anti-Infectives To Oncology
Public Company Edition: Summit initiated the big rights offering earlier this year as promised in December when it licensed Akeso’s PD-1/VEGF bispecific. Also, Teva sold $2.49bn in sustainability-linked notes to pay down debt, while MorphoSys, Novavax and others restructured and cut jobs.
AZ’s Danicopan Could Protect Ultomiris After Pivotal Combination Success In PNH
The major’s factor D inhibitor has increased hemoglobin in a subset of paroxysmal nocturnal hemoglobinuria patients when added to a C5 inhibitor, paving the way for an approval that could help protect Ultomiris from competition.
NextPoint Could Treat PD-L1 Negative Cancer Patients With HHLA2-Targeted Approach
Emerging Company Profile: Backed by strong academic talent and a recent $80m fundraising, the US biotech is on a mission to address the unmet medical need in PD-L1 negative cancer by targeting the HHLA2 pathway.